EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers
NCT07018505 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2025-06-12
Summary
For early breast cancer patients, breast-conserving surgery and sentinel lymph node biopsy have emerged as the cornerstone of precision oncology, harmonizing oncologic efficacy with the preservation of breast cosmetics and axillary function. However, conventional margin evaluation relies on subjective experience, leading to positive margin rates of 15%-50% Additionally, sentinel lymph node biopsy faces inherent technical limitations, including prolonged procedural time and significant false-negative rates in detecting micro-metastases. To overcome these challenges, the investigators will introduce a stable "sandwich" EpCAM-targeted surface-enhanced Raman spectroscopy (SERS) detection system to provide rapid evaluation of surgical margins and sentinel lymph node (SLN) metastasis status. In brief, a portion of resected tissue will be immediately homogenized by grinding, and the tissue homogenate will then be analyzed using this detection system to determine its histological characteristics. Pathological confirmation will further validate the method. This approach aims to improve the accuracy and efficiency of intraoperative assessment of breast-conserving surgical margins and SLN status, thereby effectively reducing local recurrence rates and complications.
Conditions
- Sentinel Lymph Node
- Breast Cancers
- Metastases
- Margin Assessment
Interventions
- DIAGNOSTIC_TEST
-
SERS detection
Incubation: A mixture of 20 μL (0.5 mg/mL) magnetic beads (MB@RB20115UD), 40 μL SERS nanotags (Au-IR808@RB20115UC), and prepared sample is incubated for 5 min. Washing: The supernatant is removed after magnetic separation (30 s), followed by washing with PBST (pH 7.4, 0.05% Tween-20). Detection: The separated pellet is resuspended in 10 μL ultrapure water. Then 2 μL solution is spotted onto a 2.5 mm × 2.5 mm gold substrate for air-drying. Raman spectra are acquired using a portable spectrometer (785 nm laser, 500 mW power, 5 s acquisition time, triplicate measurements). Peak areas within 540-570 cm-1 are quantified.
Sponsors & Collaborators
-
Xiang'an Hospital of Xiamen University
collaborator OTHER -
Yunnan Cancer Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-15
- Primary Completion
- 2026-06-15
- Completion
- 2026-07-01
Countries
- China
Study Locations
More Related Trials
-
Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients
NCT06780748 ·Status: RECRUITING ·Phase: PHASE2
-
Omission of SLNB in CN0 Early Breast Cancer
NCT05935150 ·Status: RECRUITING ·Phase: NA
-
Oncologic Safety of Sentinel Lymph Node Biopsy in Clinically Palpable Axillary Lymph Node in Breast Cancer Patients
NCT05703295 ·Status: UNKNOWN
-
Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive
NCT01668914 ·Status: COMPLETED ·Phase: PHASE3
-
Prediction of Non-sentinel Lymph Node Metastatic Status of Breast Cancer Based on Pathology-MRI Images
NCT06510738 ·Status: NOT_YET_RECRUITING
-
Trop2-targeting NIR-II Molecular Probe for Breast Cancer Precise Surgery
NCT06713681 ·Status: COMPLETED
-
Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy
NCT02335671 ·Status: COMPLETED ·Phase: NA
-
Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast Cancer
NCT06001528 ·Status: RECRUITING
-
Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node.
NCT05623280 ·Status: UNKNOWN
-
Sentinel Lymph Node Biopsy With or Without Para-Sentinel Lymph Node Dissection in Breast Cancer
NCT02651142 ·Status: UNKNOWN ·Phase: NA
-
Axillary Staging in Early Breast Cancer: SNB vs PET/MRI
NCT04829643 ·Status: COMPLETED ·Phase: NA
-
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
NCT06212440 ·Status: COMPLETED ·Phase: NA
-
Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy
NCT03381092 ·Status: UNKNOWN
-
Predict the Risk of Axillary Metastases in Breast Cancer Patients With Axillary Ultrasound
NCT02992769 ·Status: UNKNOWN
-
The Accuracy of Sentinel Node Biopsy of Breast Cancer With Sonographic Abnormal Axillary Lymph Nodes
NCT02005926 ·Status: COMPLETED ·Phase: PHASE2
-
Precision Regional Node Irradiation for Sentinel Node-positive Breast Cancer
NCT06583655 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)
NCT04004559 ·Status: UNKNOWN
-
Multimodal Imaging Evaluation System of Axillary Lymph Node Staging and Treatment Strategy for Breast Cancer Neoadjuvant Therapy
NCT04661436 ·Status: UNKNOWN
-
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status
NCT06713161 ·Status: RECRUITING
-
Prospective Ultrafast MRI Radiomics for Breast Cancer
NCT06104189 ·Status: COMPLETED
-
SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer
NCT03411070 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
The Validation of Sentinel Lymph Node Biopsy After Neo-adjuvant Chemotherapy in Breast Cancer Patients
NCT04986306 ·Status: UNKNOWN
-
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
NCT06559696 ·Status: RECRUITING ·Phase: PHASE3
-
Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01)
NCT04003558 ·Status: UNKNOWN
-
A Study of Tumor Imaging With Multispectral Optoacoustic Tomography
NCT05488483 ·Status: ACTIVE_NOT_RECRUITING